Methotrexate for Ectopic Pregnancy
For hemodynamically stable patients with unruptured ectopic pregnancy, administer methotrexate 50 mg/m² intramuscularly as a single dose, provided the patient meets specific eligibility criteria including β-hCG between 1500-5000 IU/L, ectopic mass <35 mm without fetal cardiac activity, and ability to return for follow-up. 1
Eligibility Criteria
The RCOG/NICE guidelines provide clear parameters for methotrexate candidacy 1:
Absolute Requirements:
- Hemodynamic stability (stable vital signs, no signs of shock)
- No significant pain (mild discomfort acceptable, but not severe abdominal pain)
- Unruptured ectopic pregnancy confirmed on ultrasound
- Ectopic mass <35 mm at greatest dimension
- No fetal cardiac activity on transvaginal ultrasound
- β-hCG level 1500-5000 IU/L (ideally <1500 IU/L for highest success)
- Confirmed absence of intrauterine pregnancy on ultrasound
- Patient willingness and ability to attend follow-up (critical for monitoring)
- No contraindications to methotrexate (no known hypersensitivity, normal renal/hepatic function, no active infection)
Important Nuances on β-hCG Levels:
While guidelines specify 1500-5000 IU/L, success rates vary dramatically by level 1:
- β-hCG <1000 IU/L: 81-98% success rate
- β-hCG 1000-5000 IU/L: Moderate success (approximately 60-80%)
- β-hCG >5000 IU/L: Only 38% success rate
Recent data confirms that baseline β-hCG <1000 mIU/mL is the strongest predictor of treatment success 2, with one 2025 study showing no successful methotrexate outcomes when β-hCG exceeded 4340 mIU/mL 2.
Dosing Regimen
Standard Protocol 1:
- Single intramuscular injection: 50 mg/m² body surface area
- Calculate body surface area using standard nomogram (height and weight)
- Alternative: Fixed-dose 90 mg protocol has shown 81% success rate 3
Monitoring Schedule:
- Day 4 post-injection: Measure serum β-hCG
- Day 7 post-injection: Measure serum β-hCG
- Assess β-hCG decline: If decrease >15% between days 4 and 7 → continue weekly monitoring until <15 IU/L
- If β-hCG decline <15%:
- Repeat transvaginal ultrasound to exclude fetal cardiac activity and hemoperitoneum
- Consider second dose of methotrexate 50 mg/m²
- 3-27% of patients require second dose 1
Weekly Follow-up:
- Continue weekly β-hCG measurements until levels fall below 15 IU/L
- Mean time to resolution: 26.5 days (range 10-37 days) 4
- Resolution can take up to 45 days in some cases 5
Critical Patient Instructions
During treatment, patients must 1:
- Avoid alcohol completely
- Avoid folate-containing vitamins (folic acid antagonizes methotrexate)
- Avoid sexual intercourse until resolution confirmed
- Use sun protection (increased photosensitivity risk)
- Report immediately: severe abdominal pain, heavy vaginal bleeding, dizziness, syncope (signs of rupture)
Common Pitfalls to Avoid
1. Treating Patients with Fetal Cardiac Activity
The presence of yolk sac, fetal pole, or cardiac activity are significant predictors of failure 1. In one study, 2 of 3 methotrexate failures had positive fetal cardiac activity 4. These patients should proceed directly to surgery.
2. Inadequate Follow-up Infrastructure
Many eligible patients ultimately require surgery due to inability to ensure reliable follow-up 2. Before prescribing methotrexate, confirm the patient has:
- Transportation to return for blood draws
- Phone access for urgent contact
- Understanding of warning signs requiring immediate ED presentation
3. Treating Rapidly Rising β-hCG
Pretreatment β-hCG kinetics matter: β-hCG increase of only 11-20% over 48 hours prior to treatment is associated with higher success 1. Rapidly rising β-hCG suggests more viable trophoblastic tissue and predicts failure.
4. Missing Contraindications
Screen for absolute contraindications 1, 6:
- Renal impairment (methotrexate is renally excreted)
- Hepatic dysfunction
- Active peptic ulcer disease
- Immunodeficiency
- Blood dyscrasias
- Breastfeeding (must discontinue for 1 week after final dose)
When to Proceed Directly to Surgery
Do not attempt methotrexate if:
- Hemodynamic instability (tachycardia, hypotension, orthostasis)
- Severe or worsening abdominal pain
- Signs of peritoneal irritation (rebound, guarding)
- Ectopic mass ≥35 mm (some use ≥40 mm cutoff 5)
- β-hCG >5000 IU/L (very low success rate)
- Fetal cardiac activity present
- Significant hemoperitoneum on ultrasound
- Patient unable to comply with follow-up
Success Rates by Clinical Scenario
Overall success: 65-95% depending on selection criteria 1
The wide range reflects study heterogeneity—some included pregnancies of unknown location that would have resolved spontaneously. The largest single study (n=559) reported 90.7% success with appropriate patient selection 1.
Ruptured but Hemodynamically Stable Patients:
One study showed 62% success in ruptured but stable patients versus 81% in unruptured cases 7. While this represents a treatment option before surgery, the lower success rate and risk of clinical deterioration make this controversial. Most guidelines recommend surgery for confirmed rupture, even if currently stable.
Predictors of Treatment Success
In order of importance 1:
- Initial β-hCG <1000 IU/L (strongest predictor)
- No gestational sac visualized on ultrasound
- β-hCG decrease from day 1 to day 4 post-treatment (88-100% success if declining)
- Minimal β-hCG rise pre-treatment (≤20% over 48 hours)
Alternative Dosing Considerations
While single-dose 50 mg/m² is standard, multi-dose regimens exist but are more complex and require more intensive monitoring. The single-dose protocol is preferred for outpatient management due to simplicity and comparable efficacy 1.
Fixed-dose 90 mg protocol is emerging as an alternative to weight-based dosing, with 81% success rate in a large cohort 3. This simplifies administration but requires institutional protocol development.
Post-Treatment Fertility
Tubal patency after successful methotrexate treatment is generally preserved. In one series, 3 of 4 women who underwent hysterosalpingography showed patency of the affected tube, and 3 women achieved spontaneous intrauterine pregnancy after treatment 5.